Nihon Chouzai
3341.TTSE PRIME
Financials · Consolidated
| Fiscal year ended | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 | 2020-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥360.5bn | ¥340.3bn | ¥313.3bn | ¥299.4bn | ¥279.0bn | ¥268.5bn |
| Operating income | ¥6.2bn | ¥9.1bn | ¥7.6bn | ¥6.6bn | ¥8.1bn | — |
| Ordinary income | ¥6.9bn | ¥9.4bn | ¥7.7bn | ¥6.8bn | ¥8.4bn | ¥7.4bn |
| Net income (owners) | ¥1.4bn | ¥2.6bn | ¥4.5bn | ¥3.7bn | ¥3.5bn | ¥6.7bn |
| Total assets | ¥197.1bn | ¥195.1bn | ¥185.3bn | ¥178.8bn | ¥186.3bn | ¥185.6bn |
| Net assets / equity | ¥59.1bn | ¥58.4bn | ¥56.5bn | ¥52.9bn | ¥49.9bn | ¥47.1bn |
| Operating cash flow | ¥8.8bn | ¥20.4bn | ¥7.5bn | ¥19.4bn | ¥11.2bn | ¥13.2bn |
| EPS (basic) | ¥46.54 | ¥85.35 | ¥148.92 | ¥123.56 | ¥118.01 | ¥223.33 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 15
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 71 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 203 figures · EDINET |
| 2023-04-01 → 2024-03-31 | AnnualAmended | 203 figures · EDINET |
| 2022-04-01 → 2023-03-31 | AnnualAmended | 203 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 71 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 203 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 203 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2021-04-01 → 2022-03-31 | AnnualAmended | 203 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 203 figures · EDINET |
23 more reports are still being processed.
Segments · FY ended 2025-03
| Segment | External sales | Profit |
|---|---|---|
| Dispensing Pharmacy Business | ¥322.0bn | ¥13.4bn |
| Medical Professional Staffing And Placement Business | ¥11.2bn | ¥937m |
| Pharmaceutical Manufacturing And Sales Business | ¥27.4bn | −¥630m |
| Adjustments & eliminations | — | −¥7.5bn |
| Total | ¥360.5bn | ¥13.8bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.